Abiopharma

🔍 Aunan Greg D (Executive)

Company: NEOGENOMICS INC (NEO)

Report Date: 2026-05-01

Detailed Transactions and Holdings:

• Sold 937 shares of Common Stock (Direct)
  Date: 2026-05-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 21,090.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 5,372 shares of Common Stock (Direct)
  Date: 2026-05-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 26,462.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 1,309 shares of Common Stock (Direct)
  Date: 2026-05-02 | Code: F | equity_swap_involved: 0 | shares_owned_after: 25,153.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 5,372 shares of Restricted Stock Unit (Derivative)
  Date: 2026-05-02 | Code: M | equity_swap_involved: 0 | shares_owned_after: 10,745.00 | transaction_form_type: 4 | Footnotes: F5, F6
• Holds 28,662 shares of Stock Option (Right to Buy) at $14.62 per share (Derivative)
  Date: 2026-05-01 | Code: H | Expires: 2030-05-01 | shares_owned_after: 28,662.00 | Footnotes: F7
• Holds 26,978 shares of Stock Option (Right to Buy) at $13.96 per share (Derivative)
  Date: 2026-05-01 | Code: H | Expires: 2034-05-02 | shares_owned_after: 26,978.00 | Footnotes: F8
• Holds 31,163 shares of Stock Option (Right to Buy) at $11.86 per share (Derivative)
  Date: 2026-05-01 | Code: H | Expires: 2035-02-21 | shares_owned_after: 31,163.00 | Footnotes: F9
• Holds 12,648 shares of Restricted Stock Unit (Derivative)
  Date: 2026-05-01 | Code: H | shares_owned_after: 12,648.00 | Footnotes: F10, F6
• Holds 36,825 shares of Stock Option (Right to Buy) at $9.83 per share (Derivative)
  Date: 2026-05-01 | Code: H | Expires: 2036-03-01 | shares_owned_after: 36,825.00 | Footnotes: F11
• Holds 22,889 shares of Restricted Stock Unit (Derivative)
  Date: 2026-05-01 | Code: H | shares_owned_after: 22,889.00 | Footnotes: F12, F6

Footnotes:

• F1: Shares surrendered to NeoGenomics, Inc. for retirement to satisfy tax obligations in connection with the May 1, 2026 vesting of restricted stock.
• F2: Reflects the release of restricted stock units that were previously reported on a Form 4.
• F3: Each restricted stock unit is economic equivalent of one share of NeoGenomics, Inc. common stock and is converted into common stock upon vesting.
• F4: Disposition of shares was in connection with the Issuer's withholding of common stock to satisfy tax withholding obligations related to the issuance of common stock upon release of restricted stock units.
• F5: On May 2, 2024, Mr. Aunan was granted 16,117 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
• F6: Once vested, the shares of common stock are not subject to expiration.
• F7: On May 1, 2023, Mr. Aunan was granted 28,662 stock options. The options vest ratably over the first four anniversary dates of the grant date.
• F8: On May 2, 2024, Mr. Aunan was granted 26,978 stock options. The options vest ratably over the first three anniversary dates of the grant date.
• F9: On February 21, 2025, Mr. Aunan was granted 31,163 stock options. The options vest ratably over the first three anniversary dates of the grant date.
• F10: On February 21, 2025, Mr. Aunan was granted 18,971 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.
• F11: On March 1, 2026, Mr. Aunan was granted 36,825 stock options. The options vest ratably over the first three anniversary dates of the grant date.
• F12: On March 1, 2026, Mr. Aunan was granted 22,889 restricted stock units. The restricted stock units vest ratably over the first three anniversary dates of the grant date.